Full Breakdown
Novo Nordisk's CagriSema Fails to Meet Weight Loss Trial Goals Against Eli Lilly's Tirzepatide
2/23/2026, 7:50:22 PM
Trial Results and Stock Impact
Novo Nordisk's experimental obesity drug, CagriSema, has failed to demonstrate non-inferiority compared to Eli Lilly's tirzepatide in a recent clinical trial, leading to a significant decline in Novo's stock price. The REDEFINE 4 trial, which lasted 84 weeks, showed that patients taking CagriSema achieved an average weight loss of 23%, while those on tirzepatide lost 25.5%. This outcome resulted in a 15% drop in Novo's shares, marking their lowest level since June 2021 and erasing gains made since the launch of its successful weight loss drug, Wegovy.
Background on CagriSema
CagriSema is a combination therapy that pairs semaglutide, the active ingredient in Wegovy and Ozempic, with cagrilintide, an experimental amylin receptor agonist. Novo Nordisk had positioned CagriSema as a potential leader in the obesity treatment market, particularly as it faces increasing competition from Eli Lilly's products, which have gained significant market share. The trial was designed as an open-label study, meaning participants were aware of their treatment, which may have introduced bias favoring the established drug, tirzepatide.
Official Statements and Responses
Novo's Chief Scientific Officer, Martin Holst Lange, expressed surprise at tirzepatide's performance, stating, "We are pleased with the weight loss of 23% for CagriSema," while emphasizing the drug's potential as the first GLP-1/amylin combination product for obesity. CEO Maziar Mike Doustdar remained optimistic, asserting, "We strongly believe that CagriSema has, right now, the best weight efficacy than any product currently in the market." However, analysts have raised concerns about CagriSema's commercial viability following the trial results.
Criticism and Opposition
Analysts have characterized the trial results as a significant setback for Novo Nordisk. J.P. Morgan analysts noted that the failure to meet the primary endpoint could dampen future revenue projections and hinder Novo's ability to regain market share in the competitive obesity treatment sector. Jefferies analyst Michael Leuchten remarked that the drug's commercial positioning is "increasingly unclear," highlighting the pressing need for mergers and acquisitions to bolster Novo's portfolio.
What's Next for Novo Nordisk?
Despite the disappointing trial results, Novo Nordisk plans to explore further trials for CagriSema, including higher-dose combinations, to assess its full weight-loss potential. The company has already submitted CagriSema for FDA approval, with a decision expected by late 2026. Analysts will be closely monitoring the outcomes of these additional studies as Novo seeks to navigate the challenges posed by increasing competition and the impending loss of exclusivity for its existing products.
Conclusion
The failure of CagriSema to match the efficacy of Eli Lilly's tirzepatide has raised significant concerns about Novo Nordisk's future in the obesity treatment market. As the company grapples with declining stock prices and increased competition, the success of its upcoming trials will be crucial in determining its ability to reclaim its position as a leader in this rapidly evolving sector.
